myCOPD
Commercial- Indications
- COPD
Company intelligence / Profile preview
The company’s suite of NHS-approved digital therapeutics—including apps for COPD, asthma, diabetes, heart disease, and COVID‑19—are deployed at scale across the UK NHS and internationally. Clinical results include improved patient engagement with self-management programs and enhanced access to rehabilitation services. For example, their COPD app has been rolled out in New Zealand as the first NHS-approved program outside the UK; their diabetes app supports over 100k patients in Kent & Medway.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on my mhealth.